CyBorD Plus Daratumumab

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)

  • Myeloma Service
  • 22-424

Sorting 4 by

Memorial Sloan Kettering Cancer Center
New York, NY
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Bergen
Montvale, NJ
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Westchester
West Harrison, NY
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Nassau
Uniondale, NY
  • Accepting patients
  • Show Principal Investigator
160 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.